We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+6.68%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.16B
AUM Growth
+$596M
(+38%)
Cap. Flow
+$655M
Cap. Flow
% of AUM
30.37%
Top 10 Holdings %
Top 10 Hldgs %
48.34%
Holding
102
New
45
Increased
15
Reduced
8
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$93.9M |
| 2 |
Biogen
BIIB
|
+$87.9M |
| 3 |
Akebia Therapeutics
AKBA
|
+$64.3M |
| 4 |
Avantor
AVTR
|
+$61.3M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$48.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$82.4M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$67.7M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$57M |
| 4 |
HOLX
Hologic
HOLX
|
+$46.6M |
| 5 |
Exelixis
EXEL
|
+$44.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.12% |
| 2 | Technology | 1.7% |
| 3 | Industrials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CTLT
26
DELISTED
CATALENT, INC.
CTLT
| $27.2M | 1.26% |
+318,100
| New | +$26.9M |
|
27
Iovance Biotherapeutics
IOVA
$2.1B
| $26.3M | 1.22% |
799,000
+60,453
| +8% | +$1.85M |
|
|
TRIL
28
DELISTED
Trillium Therapeutics Inc.
TRIL
| $24.8M | 1.15% |
+1,746,000
| New | +$17.4M |
|
29
BioXcel Therapeutics
BTAI
$26.1M
| $23.3M | 1.08% |
33,625
+9,369
| +39% | +$7.03M |
|
30
Humana
HUM
$46.7B
| $21.3M | 0.99% |
+51,500
| New | +$20.7M |
|
31
Anika Therapeutics
ANIK
$202M
| $21.3M | 0.99% |
601,700
+239,210
| +66% | +$8.64M |
|
32
Collegium Pharmaceutical
COLL
$1.16B
| $20.8M | 0.97% |
+1,000,400
| New | +$18.1M |
|
|
HARP
33
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $19.9M | 0.92% |
117,170
-3,465
| -3% | -$500K |
|
|
AMRN
34
Amarin Corp
AMRN
$293M
| $19M | 0.88% |
+225,300
| New | +$27M |
|
|
LONA
35
LeonaBio Inc
LONA
$65.5M
| $18.9M | 0.88% |
+102,634
| New | +$17.1M |
|
36
Medtronic
MDT
$111B
| $18.8M | 0.87% |
181,000
+7,300
| +4% | +$733K |
|
|
37
Exelixis
EXEL
$14.2B
| $18.8M | 0.87% |
769,200
-1,924,870
| -71% | -$44.9M |
|
|
APLS
38
DELISTED
Apellis Pharmaceuticals
APLS
| $18.8M | 0.87% |
+623,300
| New | +$18.6M |
|
|
39
Akebia Therapeutics
AKBA
$341M
| $18.4M | 0.85% |
+7,324,000
| New | +$64.3M |
|
|
ADAP
40
DELISTED
Adaptimmune Therapeutics
ADAP
| $16.6M | 0.77% |
2,084,700
+646,700
| +45% | +$5.66M |
|
|
EPIX
41
DELISTED
ESSA Pharma
EPIX
| $14.4M | 0.67% |
+2,087,800
| New | +$14.2M |
|
42
BioNTech
BNTX
$23.4B
| $14.3M | 0.66% |
+206,000
| New | +$14.8M |
|
|
MRSN
43
DELISTED
Mersana Therapeutics
MRSN
| $14.1M | 0.65% |
30,296
-12,488
| -29% | -$6.31M |
|
44
IDEAYA Biosciences
IDYA
$3.48B
| $13.2M | 0.61% |
1,050,800
-280,300
| -21% | -$3.47M |
|
45
Zymeworks
ZYME
$1.66B
| $11.4M | 0.53% |
+244,700
| New | +$8.4M |
|
46
Aldeyra Therapeutics
ALDX
$95.3M
| $10.6M | 0.49% |
+1,430,000
| New | +$9.24M |
|
47
Taysha Gene Therapies
TSHA
$1.57B
| $8.78M | 0.41% |
+392,000
| New | +$9.22M |
|
|
DVAX
48
DELISTED
Dynavax Technologies
DVAX
| $8.75M | 0.41% |
2,025,000
-649,154
| -24% | -$4.63M |
|
49
Axsome Therapeutics
AXSM
$12.1B
| $8.41M | 0.39% |
118,000
-286,900
| -71% | -$22.4M |
|
|
ITOS
50
DELISTED
iTeos Therapeutics
ITOS
| $8.14M | 0.38% |
+330,000
| New | +$8.88M |
|
Similar funds
NM
PWAM
LJAC
NI
MCM
TS
TW
PGA
Avidity Partners Management's Q3 2020 Portfolio in Review
As of Q3 2020, Avidity Partners Management held 102 positions worth $2.16B, up 38% from $1.56B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Avidity Partners Management deployed $655M of net new capital in Q3 2020, opening 45 new positions and adding to 15 existing holdings. Its largest new stake was Merck: 1,199,226 shares worth $94.9M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 92% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Exelixis, an estimated $44.9M trimmed.
- Avidity Partners Management's largest Q3 2020 buy was Merck: 1,199,226 shares worth $94.9M.
- Avidity Partners Management added most to Avantor in Q3 2020, an estimated $61.3M increase.
- Avidity Partners Management's biggest Q3 2020 reduction was Exelixis, cutting an estimated $44.9M.
- Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q3 2020, selling an estimated $82.4M.
- Avidity Partners Management's ten largest holdings make up 48% of its $2.16B portfolio in Q3 2020.
- Avidity Partners Management opened 45 new positions and closed 34 in Q3 2020.
- Avidity Partners Management's portfolio value rose 38% quarter-over-quarter to $2.16B.
Based on Avidity Partners Management's 13F filing for Q3 2020, filed 16 Nov 2020.